Cancer-related pain

Explore the linked guideline and related drug references. A matching drug entry does not establish a treatment recommendation.

WSAVA guideline

Guidelines for the Recognition, Assessment and Treatment of Pain

Reference summary — consult the linked guideline for full context

Cancer pain arises from the tumour itself (inflammation, infiltration, mechanical factors, nerve compression, tumour mediators), from diagnostics, from treatment — chemotherapy-induced peripheral neuropathy (CIPN) and radiation-associated pain (RAP) — or from unrelated causes; most cancer patients hurt at some point. Bone-tumour pain is best documented, often neuropathic-like, with widespread somatosensory sensitivity in dogs and refractoriness to oral palliation. Chronic cancer pain is treated multimodally: NSAIDs as base, adding opioids and adjuncts (e.g., gabapentin) as needed; bisphosphonates, chemotherapy and radiotherapy are beneficial, with non-drug therapies concurrent and unrelated pain (perioperative, OA) also managed.

WSAVA Guidelines for the Recognition, Assessment and Treatment of Pain (2022/2023, JSAP doi 10.1111/jsap.13566)

View on WSAVA →

Key findings

Cancer pain is multifactorial: tumour, diagnostics, treatment or unrelated; prevalence by tumour type poorly documented in animals (Cancer card; §3.14).
Bone-tumour mechanisms: invasion, microfractures, endosteal pressure, periosteal distortion, perilesional inflammation + mediators (amines, peptides, fatty acids, K⁺, prostaglandins) (§3.14).
Cancer/bone pain often has neuropathic-like signs; dogs with bone cancer show widespread sensitivity and pain refractory to oral palliative treatment (§3.14).
CIPN and RAP cause significant pain during treatment and long afterwards; mechanisms poorly understood (§3.14, Table 26).
Pain may promote cancer progression; pre-treatment pain may be negatively related to survival — treat early (§3.14).
Chronic cancer pain: multimodal — NSAIDs base + opioids + adjuncts (gabapentin) as needed; bisphosphonates/chemo/radiotherapy beneficial; non-drug therapies concurrent (card; §3.14).
Bone cancer = severe-to-excruciating (GPC perceived-pain table); CBPI validated for canine bone-cancer pain (Table 11; §1.6).

Drugs named in WSAVA’s own guideline text

As printed in WSAVA’s document, not this app’s own extracted data — see “Related drugs in this reference” below for that.

NSAIDs (base; e.g., carprofen, meloxicam) (Dog / Cat)
Base of chronic cancer pain
Opioids (added as needed) (Dog / Cat)
Moderate–severe/breakthrough pain
Gabapentin (adjunct) (Dog / Cat)
Neuropathic-like cancer pain
Bisphosphonates (Dog (& Cat))
Bone cancer pain adjunct
Mucositis wash: lidocaine 2% viscous 1:1:1 + Mg/Al hydroxide + diphenhydramine (Dog & Cat)
Radiation/chemo oral mucositis (Table 26)

Recommendations

Multimodal drug approach for chronic cancer pain
Expert consensus (GPC)
NSAIDs are the base; add opioids + adjuncts (gabapentin) as needed
Expert consensus (GPC)
Bisphosphonates, chemotherapy, radiotherapy can prove beneficial
Stated as beneficial (GPC)
Manage non-cancer pain (procedure, perioperative, OA) alongside
Expert consensus (GPC)
Non-drug therapies concurrently; adjuncts improve QoL even if analgesia unproven
Expert consensus (GPC)
Anticipate severe, often refractory bone-cancer pain
Expert consensus (GPC)
Treat early — pain may negatively affect survival
Emerging evidence (cited)
Uncontrollable pain + poor QoL → euthanasia ethically valid
Expert consensus (GPC)

Related drugs in this reference (0)

No indication text currently matches this condition by name. Try a broader condition or search the drug reference directly. Absence of a match does not establish that treatment is unavailable.

Built from the Cancer Pain card and guideline §3.14 (EN part03) vs summaries/02-pain-2022.md; the card prints no doses — doses come from formulary Tables 12, 13, 16 and Table 26 (mucositis wash).